玲瓏輪胎(601966.SH)擬以募集資金2.05億元增資廣西玲瓏以實施募投項目
格隆匯1月19日丨玲瓏輪胎(601966.SH)公佈,公司擬以募集資金2.05億元對“柳州子午線輪胎生產項目(一期續建)”募投項目實施主體廣西玲瓏進行增資。本次增資資金存儲於募集資金監管專户,專項用於柳州子午線輪胎生產項目(一期續建)的建設。
廣西玲瓏是公司全資子公司,公司對其生產經營管理活動具有絕對的控制權,本次使用募集資金向廣西玲瓏增資,是基於相關募投項目實際建設的需要,不存在改變或變相改變募集資金的投資方向和建設內容的情形,符合公司經核准的公開發行可轉換公司債券發行方案,有利於提高募集資金使用效率,符合公司的發展戰略和長遠規劃,符合公司及全體股東的利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.